Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983577 | 0.84 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7983843 | 0.78 | GRIA1 (0.61) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8477906 | 0.78 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7983673 | 0.77 | GRIA1 (0.59) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL8476223 | 0.76 | GRIA1 (0.63) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7980231 | 0.76 | GRIA1 (0.58) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL8669904 | 0.76 | GRIA1 (0.47) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL29798454 | 0.76 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL678318 | 0.76 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8476595 | 0.75 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057313-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | claimed |
| WO-1996028445-A1 | NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-09-19 | — | — | WO | claimed |
| US-6197771-B1 | NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6057313-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1996028445-A1 | NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-09-19 | — | — | WO | disclosed |